PitchSend

Investor Presentaiton

A challenging half year but growth potential remains strong Positive achievements across all our key markets Good growth in New Zealand, Asia . Good progress commercialising Maxigesic • Landmark licensing agreements with Hikma for Maxigesic IV in the US and FDA acceptance of the New Drug Application Covid-19 has impeded our progress Supply disruptions delay product launches COLD & FLU RELIEF • Delays to product launches and regulatory approvals continue • Lockdowns, travel restrictions and government- imposed limits to patient access disrupts OTC medicine sales O T AFTpharmaceuticals Natural Skin Care зиф TRA ти Page 18

View entire presentation